Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.
Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium
Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.
Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.
Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.
Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.
Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.
Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.
Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.
The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5